Live
- Three persons admitted to hospital for diarrhea treatment
- First Star Outside Milky Way Captured: WOH G64 is 2,000 Times Larger Than the Sun
- Sikkim govt to constitute state Niti Ayog: CM Tamang
- CBI books Rajasthan narcotics inspector for Rs 3 lakh bribe
- Rajasthan bypolls: A tough contest between BJP and Congress
- Albania joins SEPA, paving way for EU integration
- Japanese government approves 250-billion USD economic package to ease price pain
- Six pharma companies to set up their units in Telangana
- The Unstable Events of a 17-Wicket Day in Perth: India vs Australia
- Dutch FM's Israel trip cancelled after Netanyahu's arrest warrant
Biovet to invest Rs 200 crores for facility expansion
Biovet Private Limited, an animal vaccine maker, announced that it would invest Rs 200 crore as part of its expansion plans to meet the growing market demand for the vaccine which tackles Foot & Mouth Disease (FMD) and Brucellosis in animals.
Hyderabad: Biovet Private Limited, an animal vaccine maker, announced that it would invest Rs 200 crore as part of its expansion plans to meet the growing market demand for the vaccine which tackles Foot & Mouth Disease (FMD) and Brucellosis in animals.
Biovet informed that it commenced the work towards expanding the FMD vaccine manufacturing facility in Malur, Karnataka.
Krishna Ella, Founder, Biovet, said: "Expansion of our FMD vaccine facilities to deliver 200 million doses is an important step to increase our contribution to meet the shortage of this vaccine in the country."
The company based in Bengaluru will construct a new Brucella Vaccine Production facility at the Malur site to produce 100 million doses.
The vaccine maker said that according to estimates, India's FMD control programme requires 1,000 million doses every year, whereas the current production capacity manufactured in the country is only around 500 million doses.
There is an unmet need for 500 million doses, and Biovet aims to fulfil this gap.
